THE MEDICINES CO. –

Cambridge, Mass.

Went public 8/8/2000 at $16 per share

Filing Range: 6 mil. shares @ $14 to $16

Shares Outstanding: 28.3 mil. shares

Underwriters: J.P. Morgan & Co. Inc./Robertson Stephens & Co./CIBC

World Markets

Company Counsel: Hale & Dorr LLP

Manager Counsel: Cahill Gordon & Reindel

Auditor: Ernst & Young LLP

The Company:

Develops and acquires rights to pharmaceutical compounds. The company buys the rights to drugs in their later stages of development and leads them through clinical trials, regulatory procedures and market launch. For the company, drug development begins with an analysis and definition of the prospective medical value of a product to customers. The company’s goal is to move useful products to market faster, cheaper, and with higher quality than competitors.

Venture Backers:

E.M. Warburg, Pincus & Co. LLC

Alta Partners

Morgan Stanley Venture Partners

Moore Capital

Biotech Capital Corp.

Robertson Stephens & Co.

Morgan Stanley Dean Witter Capital Partners LLC

Remington Fund

Burr, Egan, Deleage & Co.

Alta Communications

Digital Ventures

Financing Rounds:

Number of Round Amt.

Round # Round Date Stage Investors ($ thousands)

1 09/01/1996 2 Early Stage 4500.0

2 06/01/1997 2 Expansion 24600.0

3 12/01/1997 2 Expansion 10000.0

4 08/14/1998 13 Buyout/Acquisition 36153.9

5 10/19/1999 8 Later Stage 6000.0

6 03/02/2000 6 Later Stage 13343.2

7 05/17/2000 3 Later Stage 6100.0

Financials:

(Data in $ millions)

Y/E

12/31/99

Total Revenues: $0.0

Net Income: -34.7